Celcuity announces strong Phase 3 VIKTORIA-1 results in the wild-type PIK3CA cohort and plans NDA submission in Q4 2025.

Experimental drug significantly improved wakefulness and reduced excessive daytime sleepiness in narcolepsy type 2

Pfizer acquires Metsera for $47.50 per share upfront plus $22.50 in CVRs, gaining GLP-1 and combo obesity drugs in Phase 2

Roche is acquiring 89bio for $14.50 per share plus up to $6 in CVRs tied to ambitious milestones.

United Therapeutics rose on positive Phase 3 Tyvaso data in IPF, meeting endpoints with consistent benefits across subgroups.